-
Something wrong with this record ?
(auto)imúnna trombocytopénia – diagnostika a manažment [Immune thrombocytopenia - differential diagnosis and management of thrombocytopenia]
Mária Hulíková
Language Slovak Country Slovakia
Imúnna trombocytopénia (ITP) je získané autoimúnne ochorenie, charakterizované izolovanou trombocytopéniou, ktorá môže byť spôsobená zvýšenou deštrukciou trombocytov antitrombocytovými protilátkami, ktorých cieľom sú doštičkové glykoproteíny (GP IIb/IIIa a GPIb/IX). Patogenéza ITP je multifaktoriálna. Na trombocytopénii sa okrem deštrukcie trombocytov podieľa porucha maturácie megakaryocytov, znížená produkcia megakaryocytov a trombocytov, neadekvátna odpoveď megakaryocytov na zníženie trombocytov v periférnej krvi a relatívny nedostatok endogénneho trombopoetínu (TPO). Diagnostika ITP sa opiera predovšetkým o vylúčenie inej príčiny trombocytopénie a zahŕňa anamnézu, klinický obraz, fyzikálne a laboratórne vyšetrenia. Hlavným cieľom liečby je zabezpečiť taký počet trombocytov, ktorý by zabránil závažnému krvácaniu. Stratégia liečby je zameraná na potlačenie tvorby protilátok, odstránenie miesta zániku trombocytov a stimuláciu produkcie trombocytov.
Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by isolated thrombocytopenia, which may be caused due to increased platelet destruction mediated by auto antibodies that target several platelet glycoproteins (GPIIb/ IIIa and GP Ib/IX). ITP pathogenesis is multifactorial. In thrombocytopenia, in addition to destruction of platelets, there is also involved a disorder maturation of megacaryocytes, decreased production of megacaryocytes and platelets, megacaryocytes inadequate response to a reduction in peripheral blood platelets and the relative lack of endogenous trombopoietin (TPO). Diagnosis of ITP is based primarily on the exclusion of other causes of thrombocytopenia and includes anamnesis, clinical features, physical and laboratory examinations. The main goal of treatment is to ensure such an amount of platelets which will prevent serious bleeding. Treatment strategy is aimed at suppression of antibody production, to eliminate points of platelets termination and stimulate the platelet production.
Immune thrombocytopenia - differential diagnosis and management of thrombocytopenia
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14052979
- 003
- CZ-PrNML
- 005
- 20140424120429.0
- 007
- ta
- 008
- 140402s2010 xo f 000 0|slo||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a slo
- 044 __
- $a xo
- 100 1_
- $a Hulíková, Mária $u -
- 245 10
- $a (auto)imúnna trombocytopénia – diagnostika a manažment / $c Mária Hulíková
- 246 31
- $a Immune thrombocytopenia - differential diagnosis and management of thrombocytopenia
- 520 3_
- $a Imúnna trombocytopénia (ITP) je získané autoimúnne ochorenie, charakterizované izolovanou trombocytopéniou, ktorá môže byť spôsobená zvýšenou deštrukciou trombocytov antitrombocytovými protilátkami, ktorých cieľom sú doštičkové glykoproteíny (GP IIb/IIIa a GPIb/IX). Patogenéza ITP je multifaktoriálna. Na trombocytopénii sa okrem deštrukcie trombocytov podieľa porucha maturácie megakaryocytov, znížená produkcia megakaryocytov a trombocytov, neadekvátna odpoveď megakaryocytov na zníženie trombocytov v periférnej krvi a relatívny nedostatok endogénneho trombopoetínu (TPO). Diagnostika ITP sa opiera predovšetkým o vylúčenie inej príčiny trombocytopénie a zahŕňa anamnézu, klinický obraz, fyzikálne a laboratórne vyšetrenia. Hlavným cieľom liečby je zabezpečiť taký počet trombocytov, ktorý by zabránil závažnému krvácaniu. Stratégia liečby je zameraná na potlačenie tvorby protilátok, odstránenie miesta zániku trombocytov a stimuláciu produkcie trombocytov.
- 520 9_
- $a Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by isolated thrombocytopenia, which may be caused due to increased platelet destruction mediated by auto antibodies that target several platelet glycoproteins (GPIIb/ IIIa and GP Ib/IX). ITP pathogenesis is multifactorial. In thrombocytopenia, in addition to destruction of platelets, there is also involved a disorder maturation of megacaryocytes, decreased production of megacaryocytes and platelets, megacaryocytes inadequate response to a reduction in peripheral blood platelets and the relative lack of endogenous trombopoietin (TPO). Diagnosis of ITP is based primarily on the exclusion of other causes of thrombocytopenia and includes anamnesis, clinical features, physical and laboratory examinations. The main goal of treatment is to ensure such an amount of platelets which will prevent serious bleeding. Treatment strategy is aimed at suppression of antibody production, to eliminate points of platelets termination and stimulate the platelet production.
- 653 00
- $a imúnna trombocytopénia, patogenéza, autoprotilátky, GPIIb/IIIa, GPIb/IX
- 653 00
- $a Immune thrombocytopenia, pathogenesis, autoantibodies, GPIIb/IIIa, GPIb/IX
- 773 0_
- $w MED00006500 $t Interná medicína $x 1335-8359 $g Interná med. 2010; 10 (11): 551-558
- 856 41
- $u http://samedi.sk/?page=archiv&act=Archiv_clanok&identif=interna&clanok_id=747 $y SAMEDI.sk
- 910 __
- $a ABA008 $b B 2474 $c 1045 $y -
- 990 __
- $a 20140402 $b ABA008
- 999 __
- $a ok $b bmc $g 1022215 $s 851559
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 10 $c 11 $d 551-558 $i 1335-8359 $m Interná medicína $x MED00006500
- LZP __
- $a Samedi-retro-20140402